AN OPEN, MULTICENTER STUDY OF THE EFFECTIVENESS OF ARIPIPRAZOL IN THE MANAGEMENT OF EXTERNAL ADULT PATIENTS WITH SCHIZOPHRENIA TREATED IN GENERAL PSYCHIATRIC PRACTICE

Not Applicable

• Conditions: -F20; F20

• Registration Number: PER-085-03
• Lead Sponsor: BRISTOL MYERS SQUIBB COMPANY,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2004-01-12
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

External patients men and women between the ages of 18 and 75 years presenting a diagnosis of DSM-IV schizophrenia for whom a change in the medication is clinically reasonable or the initiation of antipsychotic treatment is required. This includes patients who have symptoms that are not optimally controlled, patients experiencing tolerability problems or patients recently diagnosed with schizophrenia.

Exclusion Criteria

Women using a prohibited method of contraception.
Women who are pregnant or breastfeeding.
Women with a positive pregnancy test in the selection or prior to the administration of the study drug.

Study & Design

• Study Type: Interventional
• Study Design: Not specified